Novo Nordisk A/S Class B Profit Margin

The latest profit margin for NONOF is 35.35% as of June 2026. That compares with 35.61% in the prior-year period — down 0.7% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.

Over the past year, NONOF's profit margin moved from 35.61% to 35.35% — a 0.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novo Nordisk A/S Class B's valuation or profitability profile.

Against Healthcare companies, NONOF currently prints 35.35% for profit margin, while the sector average sits near 13.89%. That is roughly 154.4% above the sector mean. Large gaps often invite a closer look at Novo Nordisk A/S Class B's growth, margins, and balance sheet.

Profit Margin shows how effectively Novo Nordisk A/S Class B converts resources into returns. At 35.35%, NONOF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 35.61% in the prior-year period — down 0.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NONOF's profit margin (35.35%), review year-over-year change from 35.61%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.